How to access Krazati from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying a KRAS G12C mutation may receive a prescription for Krazati (adagrasib) from their treating oncologist after progression on prior systemic therapy. Krazati is FDA-approved, developed by Bristol-Myers Squibb (following the Mirati Therapeutics acquisition), and is one of the targeted options for this biomarker-defined population. In the UAE, Krazati is not yet broadly registered for routine hospital-pharmacy dispensing, which is why your oncologist may be navigating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Krazati is an oral KRAS G12C inhibitor taken twice daily. Eligibility requires molecular confirmation of a KRAS G12C mutation on tumour tissue or plasma (liquid biopsy), together with documented progression on prior systemic therapy per FDA labeling. Because Krazati is an oral therapy taken at home, the in-country infrastructure requirement is modest — your oncologist will prescribe, monitor response on imaging, and manage side-effect profile (GI, hepatic, QTc) with routine laboratory and ECG surveillance.
Is Krazati legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.
The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the physician takes clinical responsibility, and (d) the importing party documents chain of custody. For a biomarker-targeted oral oncology therapy like Krazati, the clinical rationale centres on the KRAS G12C molecular diagnosis, which MoHAP reviewers are familiar with.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Krazati is a clinical one, supported by KRAS G12C confirmation and a written rationale.
- Molecular report review. The NGS or plasma ctDNA report confirming KRAS G12C is included in the dossier.
- MoHAP named-patient application. Your physician or the hospital's importing pharmacy files the application, including clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Krazati from authorised distribution.
- Ambient shipment. Krazati tablets ship at ambient controlled conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with the oncologist's instructions for twice-daily dosing and monitoring schedule.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming KRAS G12C-mutated NSCLC, prior systemic therapy, and Krazati as the indicated next line
- Verification of their UAE medical licence
- A copy of the molecular diagnostic report confirming KRAS G12C
- Patient identifier (anonymised reference where possible)
- Planned dosing schedule and safety monitoring plan (LFTs, ECG, renal function)
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see, including the molecular-diagnostic attestation that underpins the clinical rationale for KRAS G12C targeted therapy.
Costs and timing
Krazati's US cash-pay reference price sits in an indicative 2026 range of roughly USD 21,000–24,000 for a 30-day supply, with total course cost driven by duration on therapy. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted to MoHAP. Refills ship on a rolling basis against your monthly dispensing schedule.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: Ramadan can affect the feasibility of twice-daily oral dosing with food. Your oncologist will advise whether dose timing should be adjusted during fasting periods.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Krazati specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact for your family and your physician through intake, first dispense, and refills.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. Cross-border named-patient import is a routine mechanism used across UAE oncology. See our trust and compliance page.
My NGS report is from a lab outside the UAE — is that acceptable? In practice, MoHAP reviewers accept molecular reports from accredited international laboratories for the purposes of a named-patient application. Your oncologist will confirm whether a confirmatory in-country test is also helpful.
Is there a locally registered KRAS G12C inhibitor instead? Your oncologist will confirm current UAE registration status for the KRAS G12C class. Where a registered alternative exists and is clinically equivalent, MoHAP may direct treatment to that option. Where it is not suitable, the named-patient rationale is typically supported.
How are side effects monitored? Your oncologist manages routine surveillance — laboratory tests, ECGs, imaging — locally. We coordinate refills so that there are no treatment gaps between cycles.
Will private insurance cover this? Cash-pay is the default. Some UAE insurers consider named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Krazati coordination in the UAE.
Add me to the Krazati waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.